Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ)
Shanghai, CN
Shanghai Kaibao Pharmaceutical CO.,Ltd specializes in the research, development, manufacturing, and sale of modern Traditional Chinese Medicines, primarily operating within China. Its diverse product lineup features several key pharmaceutical solutions. These include: Tanreqing injection, which is extensively utilized for addressing conditions like pneumonia, acute and chronic bronchitis, and upper respiratory tract infections. Tanreqing capsules, formulated to reduce internal heat, detoxify the system, and clear phlegm. Tiopronin for injection, designed to enhance liver function for various acute and chronic hepatitis patients. Tiopronin enteric-coated tablets, prescribed as a supplementary therapy for managing chronic hepatitis. Xiongdan dropping pills, known for their efficacy in alleviating heat, calming the liver, and promoting improved vision. Established in 2000, the company's operations are based in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | -5.00% | -7.96% | -18.53% | -16.35% | -11.77% | -13.78% | -30.00% | +13.68% | -26.32% | +13.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-21.8% Q1'26: -29.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-25.0% Q1'26: -23.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+18.6% Q1'26: +25.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+28.0% ★ Q1'26: +27.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.2% ★ Q1'26: +7.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.01× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
|---|---|
| Revenue |
1.50B
est: 1.58B (-5.0%)
|
| EBITDA |
322.68M
est: 365.22M (-11.6%)
|
| EBIT |
274.83M
est: 317.09M (-13.3%)
|
| Net Income |
226.81M
|
| SGA |
883.52M
est: 818.11M (+8.0%)
|
| EPS |
0.21
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 203.7K | 0.06% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 88.5K | 0.39% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 21.1K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.4K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.04M | 0.06% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 50.2K | 0.29% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 45.5K | 0.28% |
| 8 | Vanguard Total World Stock ETF VT | 0.00% | 334.3K | 0.06% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 13.5K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 742.7K | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianzhong Liu | Deputy GM & Non-Independent Director | — | male |
| Liwang Ren | Board Secretary & Non-Independent Director | — | male |
| Ya Ru Li | Accounting Supervisor | — | — |
| Ying Jun Zhu | Deputy General Manager | — | male |
| Yingbin Zhou | GM & Director | — | male |
| You Long Chen | Financial Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300039.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
